A Phase 2 interventional study of 300mg of TQH2722 injection and 600mg of TQH2722 injection in Sinusitis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Completed at 36 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Sinusitis with a site in China — 5 open to participants now, 7 under way, 1 of them phase 3. Sinusitis · China.
Among the 14 studies in Sinusitis with a site in China, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 2, and was the 9th registered.
256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.
Browse Sinusitis studies →5 of the 14 studies in Sinusitis with a site in China are open now. Recruiting first, the newest first:
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Sites in China
Ages 18–75
Zheng Liu · Sites in China
Ages 18–65
Enlight Medical Technologies (Shanghai) Co., Ltd · Sites in China
Ages 18+
China-Japan Union Hospital · Sites in China
Ages 18–75
Reistone Biopharma Company Limited · Sites in China
Ages 18–55 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 15 Sinusitis studies recruiting now, 6 (40%) set no upper age limit and 6 (40%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 60 across 196 interventional studies indexed under Sinusitis.
Median enrollment 79 across the 12 interventional studies, 3,439 across the 2 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. is the lead sponsor of 53 studies on the registry; 29 are open to participants now.
Sino Biopharmaceutical Limited has 1 study filed under Sinusitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Sinusitis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073664China-Japan Union HospitalA Study Evaluating the Efficacy of Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES) Combined With Stapokibart in the Treatment of Type 2 Chronic Rhinosinusitis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Sinusitis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effectiveness, safety and pharmacokinetics of TQH2722 injection in patients with chronic sinusitis with or without nasal polyps.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part B only:Participants who have had at least one blood routine test within 2 years prior to screening, or at screening, showing blood eosinophils meeting any of the following criteria:
Exclusion Criteria:
Any of the following laboratory abnormalities present at screening or randomization:
Subjects who have received any of the following treatments:
Patients with combined asthma should be excluded if they have:
The subject had concomitant diseases that prevented him/her from completing the screening period assessment or from evaluating the primary efficacy endpoint:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TQH2722 injection, 14 days as a treatment cycle.
Drug: 300mg of TQH2722 injection
TQH2722 injection, 14 days as a treatment cycle.
Drug: 600mg of TQH2722 injection
TQH2722 injection matching placebo, 14 days as a treatment cycle.
Drug: TQH2722 injection matching placebo
TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
Placebo without active substance.
Changes in the nasal polyp score of subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) from baseline at week 16 in part A
Changes in nasal polyp score from baseline in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) at week 16 in part A. The total score is 0-8 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the Lund-Mackay score of sinus CT scans of subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) from baseline at week 16 in part B
Changes in Lund-Mackay score on sinus CT scan from baseline in subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) at week 16 in part B. The total score is 0-24 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in Lund-Mackay scores of CT scans of subjects from baseline at week 16 in Part A
Changes in Lund-Mackay scores of CT scans of subjects from baseline at week 16 in Part A. The total score is 0-24 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the subjects' modified Lund-Kennedy endoscopic scores from baseline at week 16 in Part A
Changes in the subjects' modified Lund-Kennedy endoscopic scores from baseline at week 16 in Part A. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part A
Changes in the subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part A. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part A
Changes in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part A. The total score is 0-110 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16 in Part A.
Changes in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16 in Part A. The total score is 0-40 points, with the lower score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in loss-of-smell score of the subjects from baseline at week 16 in Part A
Changes in loss-of-smell score of the subjects from baseline at week 16 in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in nasal congestion score (NCS) of subjects from baseline at week 16in Part A
Changes in nasal congestion score (NCS) of subjects from baseline at week 16 in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in nasal discharge/post-nasal drip score of the subjects from baseline at week 16 in Part A
Changes in nasal discharge/post-nasal drip score of the subjects from baseline at week 16in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in facial pain/pressure score of the subjects from baseline at week 16 in Part A
Changes in facial pain/pressure score of the subjects from baseline at week 16 in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the visual analogue scale (VAS) score of the subjects from baseline at week 16in Part A
Changes in the visual analogue scale (VAS) score of the subjects from baseline at week 16 in Part A. The total score is 0-10 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in health-related quality of life (HRQoL) at Week 16 of the subjects from baseline at week 16 in Part A
Changes in health-related quality of life (HRQoL) at Week 16 of the subjects from baseline at week 16 in Part A. The Health survey short form (SF-36) total score is 0-100 points, with the higher score meaning the higher quality of life.
Time frame: Up to 16 weeks.
Changes in peak nasal inspiratory flow rate (NPIF) of the subjects from baseline at week 16 in Part A
Changes in peak nasal inspiratory flow rate (NPIF) of the subjects from baseline at week 16 in Part A
Time frame: Up to 16 weeks.
Proportion of subjects who received systemic corticosteroids (SCS) rescue therapy or surgical treatment during the 16-week treatment period in Part A
Proportion of subjects who received systemic corticosteroids (SCS) rescue therapy or surgical treatment during the 16-week treatment period s in Part A.
Time frame: Up to 16 weeks.
Incidence of adverse events in Part A
Incidence of adverse events (AES) and serious adverse events (SAEs), as well as abnormal laboratory test indicators in Part A
Time frame: Up to 24 weeks.
Severity of adverse events in Part A
Severity of adverse events (AES) and serious adverse events (SAEs), as well as abnormal laboratory test indicators in Part A
Time frame: Up to 24 weeks.
peak plasma concentration (Cmax)in Part A
Maximum plasma drug concentration in Part A
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Trough concentration (Cmin) in Part A
Minimum plasma drug concentration in Part A
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Time to peak concentration (Tmax)in Part A
The time required to reach peak concentration after administration in Part A
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Area under the plasma concentration-time curve (AUC0-t)in Part A
The area enclosed by the plasma concentration curve to the timeline in Part A.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Steady-state peak concentration (Css-max) in Part A
The highest plasma concentration that occurs in steady state in Part A.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Steady-state valley concentration (Css-min) in Part A
The lowest plasma concentration that occurs in steady state in Part A.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Average steady-state plasma concentration (Css-av) in Part A
The quotient obtained by dividing the area under the plasma concentration-time curve by the interval time τ during a dose interval when the blood concentration reaches a steady state in Part A.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Steady-state time to peak concentration (Tss-max) in Part A
The time required to reach peak steady-state concentration after administration in Part A
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Steady-state area under the plasma concentration-time curve (AUCss,0-t) in Part A
Area under the plasma concentration-time curve in steady state in Part A.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Half-life (t1/2) in Part A
The time it takes for half the drug to be eliminated from the body in Part A
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Apparent volume of distribution (Vd/F) in Part A
The ratio of the amount of drug in the body to the concentration in the blood after the drug has reached homeostasis in the body in Part A
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Clearance (CL/F) in Part A
Per unit time, the volume of drug-containing liquid is completely and effectively removed by the elimination organ in Part A
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Anti-drug antibody (ADA) positive rate of subjects in Part A
Anti-drug antibody (ADA) positive rate of subjects in Part A
Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
Titer of Anti-drug antibody (ADA) of subjects in Part A
Titer of Anti-drug antibody (ADA) of subjects in Part A
Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
Incidence of subjects with neutralizing antibodies (Nab) in Part A
Incidence of subjects with neutralizing antibodies (Nab) in Part A.
Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
Changes in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16in Part B
Changes in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16 in Part B. The total score is 0-40 points, with the lower score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in loss-of-smell score of the subjects from baseline at week 16 in Part B
Changes in loss-of-smell score of the subjects from baseline at week 16 in Part B. The total score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the subjects' modified Lund-Kennedy endoscopic scores from baseline at week 16 in Part B
Changes in the subjects' modified Lund-Kennedy endoscopic scores from baseline at week 16 in Part B. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part B
Changes in the subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part B. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part B
Changes in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part B. The total score is 0-110 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in nasal discharge/postnasal drip score of the subjects from baseline at week 16 in Part B
Changes in nasal discharge/postnasal drip score of the subjects from baseline at week 16 in Part B. The total score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in facial pain/pressure score of the subjects from baseline at week 16 in Part B
Changes in facial pain/pressure score of the subjects from baseline at week 16 in Part B. The total score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in the visual analogue scale (VAS) of the subjects from baseline at week 16s in Part B
Changes in the visual analogue scale (VAS) of the subjects from baseline at week 16 in Part B. The total score is 0-10 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Proportion of subjects who received systemic corticosteroids (SCS) rescue therapy or surgical treatment during the 16-week treatment period in Part B
Proportion of subjects who received systemic corticosteroids (SCS) rescue therapy or surgical treatment during the 16-week treatment period in Part B.
Time frame: Up to 16 weeks.
Incidence of adverse events in Part B
Incidence of adverse events (AES) and serious adverse events (SAEs), as well as abnormal laboratory test indicators in Part B.
Time frame: Up to 24 weeks.
Severity of adverse events in Part B
Severity of adverse events (AES) and serious adverse events (SAEs), as well as abnormal laboratory test indicators in Part B.
Time frame: Up to 24 weeks.
Peak plasma concentration in Part B
Maximum plasma drug concentration in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Trough concentration (Cmin) in Part B
Minimum plasma drug concentration in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Time to peak concentration (Tmax) in Part B
The time required to reach peak concentration after administration in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Area under the plasma concentration-time curve (AUC0-t)in Part B
The area enclosed by the plasma concentration curve to the timeline in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Steady-state peak concentration (Css-max) in Part B
The highest plasma concentration that occurs in steady state in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Steady-state trough concentration (Css-min) in Part B
The lowest blood concentration that occurs in steady state in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Average steady-state plasma concentration (Css-av) in Part B
The quotient obtained by dividing the area under the blood concentration-time curve by the interval time τ during a dose interval when the blood concentration reaches a steady state in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Steady-state time to peak concentration (Tss-max) in Part B
The time required to reach peak steady-state concentration after administration in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Steady-state area under the plasma concentration-time curve (AUC ss,0-t) in Part B
Area under the plasma concentration-time curve in steady state in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
half-life in Part B
The time it takes for half the drug to be eliminated from the body in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Apparent volume of distribution (Vd/F) in Part B
The ratio of the amount of drug in the body to the concentration in the blood after the drug has reached homeostasis in the body in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Clearance (CL/F) in Part B
Per unit time, the volume of drug-containing liquid is completely and effectively removed by the elimination organ in Part B.
Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
Anti-drug antibody (ADA) positive rate of subjects in Part B
Anti-drug antibody (ADA) positive rate of subjects in Part B.
Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
Titer of Anti-drug antibody (ADA) of subjects in Part B
Titer of Anti-drug antibody (ADA) of subjects in Part B.
Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
Incidence of subjects with neutralizing antibodies (Nab) in Part B
Incidence of subjects with neutralizing antibodies (Nab) in Part B.
Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
Changes in Asthma Control Questionnaire (ACQ-6) score from baseline among subjects with combined asthma in part A
Change in ACQ-6 score from baseline among subjects with combined asthma in part A. The total score ranges from 0 to 6, with higher scores indicating less well-controlled asthma
Time frame: Up to 16 weeks.
Change of total Immunoglobulin E (IgE) in peripheral blood from baseline in Part A
Change of total Immunoglobulin E (IgE) in peripheral blood from baseline in subjects at Week 16 in Part A.
Time frame: Up to 16 weeks.
Change of Eosinophil count in peripheral blood from baseline in Part A
Change of Eosinophil count in peripheral blood from baseline in subjects in Part A.
Time frame: Up to 16 weeks.
Change from baseline in peripheral blood eotaxin-3 (CCL26) concentrations in subjects in Part A
Change from baseline in peripheral blood eotaxin-3 (CCL26) concentrations in subjects at Week 16 in Part A.
Time frame: Up to 16 weeks.
Change from baseline in peripheral blood Cystatin-SN (CST1) in subjects in part A
Change from baseline in peripheral blood Cystatin-SN (CST1) in subjects at Week 16 in part A.
Time frame: Up to 16 weeks
Change from baseline in Cystatin-SN (CST1) in nasal exfoliated cells in Part A
Change from baseline in Cystatin-SN (CST1) in nasal exfoliated cells in subjects at Week 16 in Part A.
Time frame: Up to 16 weeks
Change from baseline in eotaxin-3 (CCL26) in nasal exfoliated cells in Part A
Change from baseline in eotaxin-3 (CCL26) in nasal exfoliated cells in subjects at Week 16 in Part A
Time frame: Up to 16 weeks
Change from baseline in Charcot-Leyden crystal protein (CLC) in nasal exfoliated cells in Part A
Change from baseline in Charcot-Leyden crystal protein (CLC) in nasal exfoliated cells in Part A.
Time frame: Up to 16 weeks.
Change from baseline inArachidonate 15-lipoxygenase (ALOX15) in nasal exfoliated cells in Part A
Change from baseline in Arachidonate 15-lipoxygenase (ALOX15) in nasal exfoliated cells in subjects at Week 16 in Part A
Time frame: Up to 16 weeks.
Change from baseline in cytokines in nasal secretions of Part A
Changes in cytokines in nasal secretions from baseline at week 16 of Part A.
Time frame: Up to 16 weeks
Changes in microorganisms in nasal secretions from baseline at week 16 of Part A
Change from baseline in microbiota in nasal secretions in subjects at Week 16 of Part A.
Time frame: Up to 16 weeks.
Changes in nasal congestion score (NCS) from baseline at week 16 in Part B
Change in subjects' Nasal congestion Score (NCS) from baseline at week 16 in Part B. The total score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Up to 16 weeks.
Changes in ACQ-6 scores in subjects with asthma from baseline at week 16 in part B
Change in ACQ-6 score from baseline among subjects with combined asthma in part B. The total score ranges from 0 to 6, with higher scores indicating less well-controlled asthma.
Time frame: Up to 16 weeks.
Change of total Immunoglobulin E (IgE) in peripheral blood from baseline in Part B
Change of total Immunoglobulin E (IgE) in peripheral blood from baseline in subjects at Week 16 in Part B.
Time frame: Up to 16 weeks
Change of Eosinophil count in peripheral blood from baseline in Part B
Change of Eosinophil count in peripheral blood from baseline in subjects in Part A
Time frame: Up to 16 weeks
Change from baseline in peripheral blood eotaxin-3 (CCL26) concentrations in subjects in Part B
Change from baseline in peripheral blood eotaxin-3 (CCL26) concentrations in subjects at Week 16 in Part B
Time frame: Up to 16 weeks.
Change from baseline in Cystatin-SN (CST1) in subjects in part B
Change from baseline in Cystatin-SN (CST1) in subjects at Week 16 in part B
Time frame: Up to 16 weeks.
Change from baseline in Cystatin-SN (CST1) in nasal exfoliated cells in Part B
Change from baseline in Cystatin-SN (CST1) in nasal exfoliated cells in subjects at Week 16 in Part B.
Time frame: Up to 16 weeks.
Change from baseline in eotaxin-3 (CCL26) in nasal exfoliated cells in Part B
Change from baseline in eotaxin-3 (CCL26) in nasal exfoliated cells in subjects at Week 16 in Part B.
Time frame: Up to 16 weeks.
Change from baseline in Charcot-Leyden crystal protein (CLC) in nasal exfoliated cells in Part B
Change from baseline in Charcot-Leyden crystal protein (CLC) in nasal exfoliated cells in subjects at Week 16 in Part B.
Time frame: Up to 16 weeks.
Change from baseline inArachidonate 15-lipoxygenase (ALOX15) in nasal exfoliated cells in Part B
Change from baseline in Arachidonate 15-lipoxygenase (ALOX15) in nasal exfoliated cells in subjects at Week 16 in Part B.
Time frame: Up to 16 weeks.
Change from baseline in cytokines in nasal secretions of Part B
Changes in cytokines in nasal secretions from baseline at week 16 of Part B.
Time frame: Up to 16 weeks.
Change from baseline in microbiota in nasal secretions of Part B
Changes in microorganisms in nasal secretions from baseline at week 16 of Part B.
Time frame: Up to 16 weeks.
Changes in health-related quality of life (HRQoL) at Week 16 of the subjects from baseline at week 16 in Part B
Changes in health-related quality of life (HRQoL) at Week 16 of the subjects from baseline at week 16 in Part B. The Health survey short form (SF-36) total score is 0-100 points, with the higher score meaning the higher quality of life.
Time frame: Up to 16 weeks.
Ran from Dec 2023 to primary completion in Mar 2025, 15 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. →